Study identifier:D6933C00002
ClinicalTrials.gov identifier:NCT06502366
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12-Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma
asthma
Phase 3
No
BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFA
All
398
Interventional
18 Years - n/a
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: BDA MDI HFO 160/180 µg Budesonide/albuterol pressurized inhalation suspension, HFO | Drug: BDA MDI HFO 160/180 μg Budesonide/albuterol pressurized inhalation suspension, HFO |
Active Comparator: BDA MDI HFA 160/180 µg Budesonide/albuterol pressurized inhalation suspension, HFA | Drug: BDA MDI HFA 160/180 μg Budesonide/albuterol pressurized inhalation suspension, HFA |
Placebo Comparator: Placebo MDI HFA Placebo pressurized inhalation suspension, HFA | Drug: Placebo MDI HFA Placebo pressurized inhalation suspension, HFA |